Latest Industry Insights

Technology Networks recently spoke with Santhosh Nair to learn more about polyautoimmunity and the evolving role of clinical laboratories in its detection and management.

In this interview, Dr. Anderson discusses the advantages of dd-cfDNA as a transplant monitoring tool and the regulatory and clinical hurdles that must be overcome before dd-cfDNA testing can be fully adopted in healthcare.

Technology Networks asked a selection of start-up companies featured in the ELRIG Drug Discovery 2025 Breakthrough Zone how their technology could help realize the full capabilities of precision medicine.

Technology Networks spoke with Dr. Olga Colgan and Dr. Joseph Chiweshe to learn how AI-driven digital pathology is reshaping diagnostic workflows.

Dr. Heidi Rehm shares insights on how genomics is evolving at the intersection of research and clinical practice. In this Q&A, she highlights the role of AI, global data standards and collaboration in shaping future patient care.

In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.

In this interview, Dr. Denise Teber, a scientific expert in molecular biology at Charles River Laboratories, discusses how ddPCR is being used to improve contamination risk management.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

We spoke with Castle Bioscience's Dr. Rebecca Critchley-Thorne about AI-enabled spatial proteomics, TissueCypher’s impact on Barrett’s esophagus management and its broader potential for precision oncology.

As global scientific and regulatory landscapes shift, companies across the life sciences sector are under growing pressure to adapt. Hear how Phenomenex are taking a proactive approach.